10JUN12I drew the following chart last Thursday night for a friend, updated with Friday's price action. My thoughts were that it was rejected by the 4hr donut (.886 fib) on Thursday and so more downside before support around 1.74-.70. ...
Shares of MannKind Corp (MNKD.O) rose as much as 33 percent on Friday, a day after the company said U.S. regulators cleared the design of two clinical studies to test the efficacy and...(read more
There was some good news for MannKind Corporation’s (MNKD) lead pipeline candidate, Afrezza, when the US Food and Drug Administration (FDA) rescheduled its...(read more
MannKind (MNKD) Company Overview
MannKind is a biopharmaceutical company focused on the discovery, development, and commercialization of therapeutic products for diabetes, cancer, and inflammatory and autoimmune diseases. The company's lead product, the Technosphere Insulin System, meant for the treatment of diabetes, is in a series of pivotal phase III trial in the U.S. This product utilizes MannKind s proprietary dry powder Technosphere formulation of insulin. It is inhaled deep into the lungs using the company s MedTone inhaler. Besides the company s development of Technosphere, MannKind is pursuing efforts aimed at the discovery and development of novel drugs for metabolic and immunological diseases. The company also has early-stage development programs for the treatment of solid-tumor cancers. MannKind initiated phase I trials with its cancer candidates in early 2007. MannKind's corporate headquarters and immunology research operations are located in Valencia, CA. Significant operations, including the Technosphere Insulin research, development and manufacturing are located in Danbury, CT. The company's initial public offering (IPO) took place in late July 2004.
(Read more at Wikinvest )